RP1 and Other Oncolytic Viruses Could Pave a New Treatment Pathway in Advanced Melanoma
Source: Onclive, December 2024
Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.
With immune checkpoint inhibitors established as the standard frontline treatment for patients with advanced melanoma, investigations into other immune-based therapies such as oncolytic viruses aim to bolster the treatment armamentarium for patients in need of subsequent treatments after progression on an anti–PD-1 regimen, according to Bently P. Doonan, MD.
“Melanoma [treatment] has shown a ton of up-front success, but it doesn’t have a deep bench. Once those [initial treatments] get tired, we really don’t have anything significantly beneficial [in subsequent lines of therapy],” Doonan explained.